Harley-Davidson's stock is in a recovery uptrend from its 52-week low of $17.09, with the current price of $25.14 representing 80.5% of the 52-week range ($17.09–$31.25). The 1-year price change is +11.95%, significantly underperforming the S&P 500's +20.63% over the same period, indicating relative weakness. The stock's beta of 1.273 suggests it is 27.3% more volatile than the market, amplifying both upside and downside moves. Short-term momentum is positive: the 1-month price change is +2.95% and the 3-month change is +10.31%, both accelerating from the longer-term trend. However, the 1-month relative strength vs. SPY is -1.12%, meaning the stock has lagged the market in the most recent month. This divergence could signal a temporary pullback within an ongoing recovery, as the 6-month relative strength is +8.54%, indicating medium-term outperformance. The 52-week high of $31.25 acts as key resistance; a breakout above this level would signal a resumption of the long-term uptrend and could target the next resistance near $35. Conversely, the 52-week low of $17.09 provides strong support; a breakdown below this level would likely indicate a continuation of the prior downtrend. With a beta of 1.273, the stock is more volatile than the market, meaning larger price swings that require careful position sizing.

Revenue has been declining sharply: the most recent quarter (Q4 2025) reported revenue of $496.2 million, a 27.84% year-over-year decline. This follows a pattern of deceleration from Q1 2025 revenue of $1.33 billion (down from $1.73 billion in Q1 2024). The trailing twelve-month revenue is approximately $4.47 billion, down from $5.19 billion in the prior TTM period. The decline is broad-based, with motorcycle revenue of $193.9 million in Q4 2025 being the largest segment but still insufficient to offset losses. The company is unprofitable on a GAAP basis: Q4 2025 net income was -$279.3 million, with a net margin of -56.3%. Gross margin turned negative at -22.8%, reflecting severe cost pressures or inventory write-downs. However, earlier quarters in 2025 showed positive gross margins (Q3: 35.2%, Q2: 28.2%, Q1: 35.3%), indicating the Q4 loss may be seasonal or impairment-related. Operating margin in Q4 was -72.8%, a dramatic swing from Q3's +35.7%. The company's balance sheet shows a debt-to-equity ratio of 0.97, which is manageable but elevated. Free cash flow for the TTM was $415.2 million, though Q4 2025 operating cash flow was $152 million with capex of $51.6 million, yielding FCF of $100.4 million. The current ratio of 2.10 indicates adequate liquidity, and ROE of 10.8% is reasonable but distorted by the recent loss. The company generates enough cash to cover its dividend (payout ratio 25.5%), but the declining revenue trend raises concerns about future cash generation.